Adaptam Therapeutics, a San Sebastian-based firm pioneering most cancers immunotherapies particularly concentrating on immunosuppressive myeloid cells, right now broadcasts the profitable completion of a €3 million pre-Seed financing spherical
The spherical was led by Standards Bio Ventures and can allow Adaptam to additional develop its programmes and enter the preclinical part in a number of oncology indications. As a part of the spherical, Salvatore Cappadona, PhD, and Pablo Cironi, PhD, each from Standards Bio Ventures, joined the board of administrators.
“Immunosuppressive myeloid cells inside tumors current one of many hardest challenges in immunotherapy right now. Our aim is to neutralise this impediment by creating therapies that particularly goal these cells, providing sufferers new hope the place conventional approaches have failed,” mentioned Asis Palazon, PhD, founder, CEO and CSO of Adaptam.
This newly introduced pre-Seed spherical for Adaptam locations it alongside different 2025 European immuno-oncology ventures which have lately secured capital. Notably, this Spanish BioTech is addressing immunosuppressive myeloid cells within the tumour microenvironment – a extra particular goal in contrast with a few of the broader tumour-targeted therapies funded elsewhere.
In France, Exeliom Biosciences raised €2.85 million to speed up its immunotherapy programmes for most cancers. From Sweden, Lithea AB secured €851k to advance a tumour-targeted remedy for childhood bone most cancers. In the meantime, Trogenix in the UK closed an €80 million Sequence A to speed up the event of healing most cancers therapies.
Whereas these rounds differ considerably in scale and medical maturity, they collectively point out sustained investor confidence in European oncology innovation. Adaptam’s pre-clinical concentrate on glyco-immune checkpoint modulation provides a particular Spanish contribution to this broader regional momentum in most cancers immunotherapy.
“The assist from Standards Bio Ventures allows us to take a step ahead in reaching our mission. We at the moment are actively planning our next funding spherical to assist IND-enabling research,” added Palazon.
Based in 2023, Adaptam is a BioTech spin-off from CIC bioGUNE creating first-in-class antibody therapies for strong tumours.
Adaptam originated from analysis performed by Prof. Asis Palazon and his workforce at CIC bioGUNE in Bilbao, Spain, with skilled insights from Standards Bio Ventures on the ideation, company technique and operational setup of the corporate.
The corporate particularly targets the immunosuppressive myeloid tumor microenvironment by unexplored glyco-immune checkpoints, that are expressed in immunosuppressive myeloid cells equivalent to tumor-associated macrophages (TAMs).
Adaptam is advancing antibody-drug conjugates (ADCs) and bispecific antibodies as a part of its differentiated pipeline. The corporate, backed by Standards Bio Ventures and ERC funding, is dedicated to delivering new remedy choices in immuno-oncology.
“We’re thrilled to assist Adaptam in its mission to remodel most cancers remedy by concentrating on the immunosuppressive cells inside the TME. The scientific breakthroughs achieved by Prof. Asis Palazon and his workforce have laid the groundwork for probably life-changing therapies,” mentioned Pablo Cironi, PhD, chairman of the Adaptam board. “With this sturdy basis, we imagine Adaptam is well-positioned to ship new, efficient therapies for sufferers with strong tumors, addressing vital gaps in present immunotherapy choices.”
Immunotherapy has remodeled most cancers remedy, providing new options to sufferers worldwide. Nevertheless, the corporate says a big quantity nonetheless fail to reply to these therapies or develop resistance over time.
This lack of efficacy is reprotedly because of the immunosuppressive nature of the tumour microenvironment (TME), which hampers the immune system’s potential to successfully goal and destroy most cancers cells. Among the many principal contributors to this immunosuppression are myeloid cells, significantly TAMs, which play an important function in inhibiting T-cell responses.
This problem is especially pronounced in sufferers with strong tumors, the place these myeloid cells create an surroundings that stops immune cells from mounting an efficient anti-tumoral response.
“Adaptam’s differentiated strategy on the intersection of myeloid-mediated immunosuppression and glycobiology represents a one-of-a-kind imaginative and prescient uniquely positioned to unlock the following frontier in most cancers immunotherapy. We’re proud to have partnered with Asis Palazon to construct this thrilling new enterprise and assist its subsequent part of improvement.
“We’re assured that Adaptam’s rising pipeline provides a game-changing alternative to remodel most cancers remedy for a lot of sufferers,” mentioned Salvatore Cappadona, PhD, board member of Adaptam.
Among the core structural and mechanistic discoveries of immune-modulating glycan-binding proteins and their interactions with immune cells have been beforehand revealed in Nature Communications.
“CIC bioGUNE’s long-standing management in glycobiology offered the scientific basis for Adaptam and now we have supported the corporate from its earliest steps by to right now’s preclinical maturation,” mentioned Prof. Jesús Jiménez-Barbero, scientific director of CIC bioGUNE.
